Skip to main content
Top
Published in: Malaria Journal 1/2013

Open Access 01-12-2013 | Research

Anti-erythropoietin antibody levels and its association with anaemia in different strains of semi-immune mice infected with Plasmodium berghei ANKA

Authors: Gideon Kofi Helegbe, Nguyen Tien Huy, Tetsuo Yanagi, Mohammed Nasir Shuaibu, Mihoko Kikuchi, Mahamoud Sama Cherif, Kenji Hirayama

Published in: Malaria Journal | Issue 1/2013

Login to get access

Abstract

Background

Malaria anaemia is still a major public health problem and its pathogenesis still unclear. Interestingly, the progression of anaemia is at relatively low parasitaemia with some mortality in the semi-immune individuals in the endemic areas despite adequate erythropoietin (EPO) synthesis. A recent study has shown that treatment with exogenous anti-erythropoietin (anti-EPO) antibodies (Ab) of infected mice gives protection against malaria infection, suggesting an important role for anti-EPO Ab in malaria. The objective of the study was to evaluate anti-EPO antibody levels in anaemic condition of different strains of semi-immune mice with malaria.

Methodology

Semi-immune status was attained in four mice strains (Balb/c, B6, CBA and NZW) by repeated infections with 104Plasmodium berghei ANKA, and treatment with chloroquine/pyrimethamine. ELISA was used to measure anti-EPO Ab, transferrin and EPO while inflammatory cytokines measurement was done using bead-based multiplex assay kit.

Results

The mean anti-EPO Ab levels in the mice strains [Optical Density (OD) values at 450 nm: Balb/c (2.1); B6 (1.3); CBA (1.4) and NZW (1.7)] differed (p = 0.045), and were significantly higher when compared with uninfected controls, p < 0.0001, and mean anti-EPO Ab levels in the mice strains at recovery [OD values at 450 nm: Balb/c (1.8); B6 (1.1); CBA (1.5) and NZW (1.0) also differed (p = 0.0004). Interestingly, EPO levels were significantly high in NZW and low in Balb/c mice (p < 0.05), with those of B6 and CBA of intermediary values. Again, NZW were highly parasitaemic (20.7%) and the other strains (Balb/c, B6 and CBA) ranged between 2.2-2.8% (p = 0.015). Anti-EPO Ab correlated positively with extent of Hb loss (r = 0.5861; p = 0.003). Correlation of anti-EPO antibody with EPO was significant only in Balb/c mice (r = −0.83; p = 0.01). Significant levels of IL6 and IFNγ (p < 0.0001), both known to be associated with erythropoiesis suppression were observed in the Balb/c. Transferrin was significantly lower in Balb/c (p < 0.0001) when compared with the other mice strains (B6, CBA and NZW).

Conclusion

This is the first ever report in estimating endogenous anti-EPO antibodies in malaria anaemia. The data presented here suggest that anti-EPO Ab is produced at infection and is associated with Hb loss. Host factors appear to influence anti-EPO antibody levels in the different strains of mice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L: Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. Blood. 2006, 107: 1192-1199.PubMedCentralCrossRefPubMed Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L: Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. Blood. 2006, 107: 1192-1199.PubMedCentralCrossRefPubMed
2.
go back to reference Helegbe GK, Huy NT, Yanagi T, Shuaibu MN, Yamazaki A, Kikuchi M, Yasunami M, Hirayama K: Rate of red blood cell destruction varies in different strains of mice infected with Plasmodium berghei- ANKA after chronic exposure. Malar J. 2009, 8: 91-10.1186/1475-2875-8-91.PubMedCentralCrossRefPubMed Helegbe GK, Huy NT, Yanagi T, Shuaibu MN, Yamazaki A, Kikuchi M, Yasunami M, Hirayama K: Rate of red blood cell destruction varies in different strains of mice infected with Plasmodium berghei- ANKA after chronic exposure. Malar J. 2009, 8: 91-10.1186/1475-2875-8-91.PubMedCentralCrossRefPubMed
3.
go back to reference Weatherall DJ, Abdalla S: The anaemia of Plasmodium falciparum malaria. Br Med Bull. 1982, 38: 147-151.PubMed Weatherall DJ, Abdalla S: The anaemia of Plasmodium falciparum malaria. Br Med Bull. 1982, 38: 147-151.PubMed
4.
go back to reference Menendez C, Fleming AF, Alonso PL: Malaria-related anaemia. Parasitol Today. 2000, 16: 469-476. 10.1016/S0169-4758(00)01774-9.CrossRefPubMed Menendez C, Fleming AF, Alonso PL: Malaria-related anaemia. Parasitol Today. 2000, 16: 469-476. 10.1016/S0169-4758(00)01774-9.CrossRefPubMed
5.
go back to reference Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, Hviid L: Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol. 1997, 97: 169-174. 10.1046/j.1365-2141.1997.82654.x.CrossRefPubMed Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, Hviid L: Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol. 1997, 97: 169-174. 10.1046/j.1365-2141.1997.82654.x.CrossRefPubMed
6.
go back to reference Yap GS, Stevenson MM: Plasmodium chabaudi AS: erythropoietic responses during infection in resistant and susceptible mice. Exp Parasitol. 1992, 75: 340-352. 10.1016/0014-4894(92)90219-Z.CrossRefPubMed Yap GS, Stevenson MM: Plasmodium chabaudi AS: erythropoietic responses during infection in resistant and susceptible mice. Exp Parasitol. 1992, 75: 340-352. 10.1016/0014-4894(92)90219-Z.CrossRefPubMed
7.
go back to reference Chang KH, Stevenson MM: Comparison of murine Epo ELISA and Epo bioassays in detecting serum Epo levels during anemia associated with malaria infection. J Immunol Meth. 2002, 262: 129-136. 10.1016/S0022-1759(02)00012-1.CrossRef Chang KH, Stevenson MM: Comparison of murine Epo ELISA and Epo bioassays in detecting serum Epo levels during anemia associated with malaria infection. J Immunol Meth. 2002, 262: 129-136. 10.1016/S0022-1759(02)00012-1.CrossRef
8.
go back to reference Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. NEJM. 1996, 334: 630-633. 10.1056/NEJM199603073341004.CrossRefPubMed Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. NEJM. 1996, 334: 630-633. 10.1056/NEJM199603073341004.CrossRefPubMed
9.
go back to reference Tzioufas AG, Kokori SI, Petrovas CI, Moutsopoulos HM: Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum. 1997, 40: 2212-2216. 10.1002/art.1780401216.CrossRefPubMed Tzioufas AG, Kokori SI, Petrovas CI, Moutsopoulos HM: Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum. 1997, 40: 2212-2216. 10.1002/art.1780401216.CrossRefPubMed
10.
go back to reference Tsiakalos A, Kordossis T, Ziakas PD, Kontos AN, Kyriaki D, Sipsas NV: Circulating antibodies to endogenous erythropoietin and risk for HIV-1-related anemia. J Infect. 2010, 60: 238-243. 10.1016/j.jinf.2009.12.013.CrossRefPubMed Tsiakalos A, Kordossis T, Ziakas PD, Kontos AN, Kyriaki D, Sipsas NV: Circulating antibodies to endogenous erythropoietin and risk for HIV-1-related anemia. J Infect. 2010, 60: 238-243. 10.1016/j.jinf.2009.12.013.CrossRefPubMed
11.
go back to reference Chang KH, Tam M, Stevenson MM: Modulation of the course and outcome of blood-stage malaria by erythropoietin-induced reticulocytosis. The J Infect Dis. 2004, 189: 735-743. 10.1086/381458.CrossRefPubMed Chang KH, Tam M, Stevenson MM: Modulation of the course and outcome of blood-stage malaria by erythropoietin-induced reticulocytosis. The J Infect Dis. 2004, 189: 735-743. 10.1086/381458.CrossRefPubMed
12.
go back to reference Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JA: Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria. Malar J. 2008, 7: 3-10.1186/1475-2875-7-3.PubMedCentralCrossRefPubMed Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JA: Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria. Malar J. 2008, 7: 3-10.1186/1475-2875-7-3.PubMedCentralCrossRefPubMed
13.
go back to reference Moore RD, Keruly JC, Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998, 19: 29-33. 10.1097/00042560-199809010-00004.CrossRefPubMed Moore RD, Keruly JC, Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998, 19: 29-33. 10.1097/00042560-199809010-00004.CrossRefPubMed
14.
go back to reference Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D: Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006, 21: 330-336. 10.1093/ndt/gfi177.CrossRefPubMed Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D: Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006, 21: 330-336. 10.1093/ndt/gfi177.CrossRefPubMed
15.
go back to reference Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000, 97: 10526-10531. 10.1073/pnas.97.19.10526.PubMedCentralCrossRefPubMed Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000, 97: 10526-10531. 10.1073/pnas.97.19.10526.PubMedCentralCrossRefPubMed
16.
go back to reference Erslev AJ: Erythropoietin titers in health and disease. Semin Hematol. 1991, 28: 2-7. discussion 7–8PubMed Erslev AJ: Erythropoietin titers in health and disease. Semin Hematol. 1991, 28: 2-7. discussion 7–8PubMed
17.
go back to reference Harrison PR: Haemopoiesis: molecular control of Haemopoiesis. 1991, Chichester: John Wiley & Sons, Ltd edn Harrison PR: Haemopoiesis: molecular control of Haemopoiesis. 1991, Chichester: John Wiley & Sons, Ltd edn
18.
go back to reference Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. NEJM. 2002, 346: 469-475. 10.1056/NEJMoa011931.CrossRefPubMed Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. NEJM. 2002, 346: 469-475. 10.1056/NEJMoa011931.CrossRefPubMed
19.
go back to reference Tsubata S, Ebe K, Kawamura T, Ishimoto Y, Tomiyama-Miyaji C, Watanabe H, Sekikawa H, Aoyagi Y, Abo T: Protection against malaria by anti-erythropoietin antibody due to suppression of erythropoiesis in the liver and at other sites. Immunol Cell Biol. 2005, 83: 638-642. 10.1111/j.1440-1711.2005.01385.x.CrossRefPubMed Tsubata S, Ebe K, Kawamura T, Ishimoto Y, Tomiyama-Miyaji C, Watanabe H, Sekikawa H, Aoyagi Y, Abo T: Protection against malaria by anti-erythropoietin antibody due to suppression of erythropoiesis in the liver and at other sites. Immunol Cell Biol. 2005, 83: 638-642. 10.1111/j.1440-1711.2005.01385.x.CrossRefPubMed
20.
go back to reference Collicutt NB, Grindem CB, Neel JA: Comparison of manual polychromatophilic cell and automated reticulocyte quantification in evaluating regenerative response in anemic dogs. Vet Clin Pathol. 2012, 41: 256-260. 10.1111/j.1939-165X.2012.00432.x.CrossRefPubMed Collicutt NB, Grindem CB, Neel JA: Comparison of manual polychromatophilic cell and automated reticulocyte quantification in evaluating regenerative response in anemic dogs. Vet Clin Pathol. 2012, 41: 256-260. 10.1111/j.1939-165X.2012.00432.x.CrossRefPubMed
22.
go back to reference Akanmori BD, Kurtzhals JA, Goka BQ, Adabayeri V, Ofori MF, Nkrumah FK, Behr C, Hviid L: Distinct patterns of cytokine regulation in discrete clinical forms of Plasmodium falciparum malaria. Eur Cytokine Netw. 2000, 11: 113-118.PubMed Akanmori BD, Kurtzhals JA, Goka BQ, Adabayeri V, Ofori MF, Nkrumah FK, Behr C, Hviid L: Distinct patterns of cytokine regulation in discrete clinical forms of Plasmodium falciparum malaria. Eur Cytokine Netw. 2000, 11: 113-118.PubMed
23.
go back to reference Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V: A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis. 1999, 179: 279-282. 10.1086/314548.CrossRefPubMed Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V: A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis. 1999, 179: 279-282. 10.1086/314548.CrossRefPubMed
24.
go back to reference Gwamaka M, Kurtis JD, Sorensen BE, Holte S, Morrison R, Mutabingwa TK, Fried M, Duffy PE: Iron deficiency protects against severe Plasmodium falciparum malaria and death in young children. Clin Infect Dis. 2012, 54: 1137-1144. 10.1093/cid/cis010.PubMedCentralCrossRefPubMed Gwamaka M, Kurtis JD, Sorensen BE, Holte S, Morrison R, Mutabingwa TK, Fried M, Duffy PE: Iron deficiency protects against severe Plasmodium falciparum malaria and death in young children. Clin Infect Dis. 2012, 54: 1137-1144. 10.1093/cid/cis010.PubMedCentralCrossRefPubMed
26.
go back to reference de Mast Q, van Dongen-Lases EC, Swinkels DW, Nieman AE, Roestenberg M, Druilhe P, Arens TA, Luty AJ, Hermsen CC, Sauerwein RW, van der Ven AJ: Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. Br J Haematol. 2009, 145: 657-664. 10.1111/j.1365-2141.2009.07664.x.CrossRefPubMed de Mast Q, van Dongen-Lases EC, Swinkels DW, Nieman AE, Roestenberg M, Druilhe P, Arens TA, Luty AJ, Hermsen CC, Sauerwein RW, van der Ven AJ: Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. Br J Haematol. 2009, 145: 657-664. 10.1111/j.1365-2141.2009.07664.x.CrossRefPubMed
28.
go back to reference Chang SH, Dong C: A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007, 17: 435-440.PubMed Chang SH, Dong C: A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007, 17: 435-440.PubMed
29.
go back to reference Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, Qiu D, Wei J, Liu Y, Shen L, Chen X, Peng Y, Li Z, Ma X: Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011, 6: e18909-10.1371/journal.pone.0018909.PubMedCentralCrossRefPubMed Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, Qiu D, Wei J, Liu Y, Shen L, Chen X, Peng Y, Li Z, Ma X: Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011, 6: e18909-10.1371/journal.pone.0018909.PubMedCentralCrossRefPubMed
30.
go back to reference Moos T, Rosengren Nielsen T, Skjorringe T, Morgan EH: Iron trafficking inside the brain. J Neurochem. 2007, 103: 1730-1740. 10.1111/j.1471-4159.2007.04976.x.CrossRefPubMed Moos T, Rosengren Nielsen T, Skjorringe T, Morgan EH: Iron trafficking inside the brain. J Neurochem. 2007, 103: 1730-1740. 10.1111/j.1471-4159.2007.04976.x.CrossRefPubMed
31.
go back to reference Mayle KM, Le AM, Kamei DT: The intracellular trafficking pathway of transferrin. Biochim Biophys Acta. 1820, 2012: 264-281. Mayle KM, Le AM, Kamei DT: The intracellular trafficking pathway of transferrin. Biochim Biophys Acta. 1820, 2012: 264-281.
32.
go back to reference Haddad G, Belosevic M: Transferrin-derived synthetic peptide induces highly conserved pro-inflammatory responses of macrophages. Mol Immunol. 2009, 46: 576-586. 10.1016/j.molimm.2008.07.030.CrossRefPubMed Haddad G, Belosevic M: Transferrin-derived synthetic peptide induces highly conserved pro-inflammatory responses of macrophages. Mol Immunol. 2009, 46: 576-586. 10.1016/j.molimm.2008.07.030.CrossRefPubMed
33.
go back to reference Macedo MF, de Sousa M: Transferrin and the transferrin receptor: of magic bullets and other concerns. Inflamm Allergy Drug Targets. 2008, 7: 41-52. 10.2174/187152808784165162.CrossRefPubMed Macedo MF, de Sousa M: Transferrin and the transferrin receptor: of magic bullets and other concerns. Inflamm Allergy Drug Targets. 2008, 7: 41-52. 10.2174/187152808784165162.CrossRefPubMed
Metadata
Title
Anti-erythropoietin antibody levels and its association with anaemia in different strains of semi-immune mice infected with Plasmodium berghei ANKA
Authors
Gideon Kofi Helegbe
Nguyen Tien Huy
Tetsuo Yanagi
Mohammed Nasir Shuaibu
Mihoko Kikuchi
Mahamoud Sama Cherif
Kenji Hirayama
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2013
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-12-296

Other articles of this Issue 1/2013

Malaria Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.